Evidence map›Paper›PMID 37760572›Full record

ArticleCancers2023

Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study.

Carles Pericay, Ana Fernández Montes, Vicente Alonso Orduña, Ismael Macias Declara, Elena Asensio Martínez, Nuria Rodríguez Salas, Esperanza Torres, Diego Cacho Lavín, Rosa María Rodríguez Alonso, Esther Falcó and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Carles PericayServicio de Oncología Médica, Hospital Universitario Mútua Terrassa, Plaça del Doctor Robert, 5., 08221 Terrassa, Spain.ORCID 0000-0002-4975-7851
Ana Fernández MontesServicio de Oncología Médica, Complexo Hospitalario Universitario de Ourense, Calle Ramón Puga Noguerol, 54., 32005 Ourense, Spain.ORCID 0000-0003-4630-5830
Vicente Alonso OrduñaServicio de Oncología Médica, Hospital Universitario Miguel Servet, Instituto de Investigacion Sanitaria de Aragon, Paseo Isabel la Católica, 1-3., 50009 Zaragoza, Spain.
Ismael Macias DeclaraInstitut d'Investigació I Innovació I3PT, Fundació Parc Taulí, Plaça Taulí, 1., 08208 Sabadell, Spain.
Elena Asensio MartínezServicio de Oncología Médica, Hospital General Universitario de Elche, Carrer Almazara, 11., 03203 Elche, Spain.
Nuria Rodríguez SalasServicio de Oncología Médica, Hospital Universitario La Paz, Paseo de la Castellana, 261., 28046 Madrid, Spain.
Esperanza TorresUGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria and Instituto de Investigación Biomédica de Málaga (IBIMA), Campus de Teatinos, S/N, 29010 Málaga, Spain.
Diego Cacho LavínServicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
Rosa María Rodríguez AlonsoServicio de Oncología Médica, Hospital Universitario Reina Sofía-Córdoba, Avenida Menéndez Pidal s/n., 14004 Córdoba, Spain.
Esther FalcóServicio de Oncología Médica, Hospital de Son Llàtzer, Carretera de Manacor, 07198 Palma de-Mallorca, Spain.
Joan Carles OlivaInstitut d'Investigació I Innovació I3PT, Fundació Parc Taulí, Plaça Taulí, 1., 08208 Sabadell, Spain.
Lluis CireraServicio de Oncología Médica, Hospital Universitario Mútua Terrassa, Plaça del Doctor Robert, 5., 08221 Terrassa, Spain.
Institute of Research and Innovation Parc Tauli · ESMútua Terrassa · ESComplexo Hospitalario Universitario A Coruña · ESHospital General Universitario de Elche · ESHospital Son Llatzer · ESHospital Universitario La Paz · ESHospital Universitario Miguel Servet · ESHospital Universitario Reina Sofía · ESInstituto de Investigación Biomédica de Málaga · ESMarqués de Valdecilla University Hospital · ES

Funding

Merck, S.L., Spain, an affiliate of Merck KGaA, Darmstadt, Germany. The research, editorial assistance for the preparation of this article, and APC for the publication of this article.
6 · The paper itself

Abstract

The retrospective, observational RWD-ACROSS study analyzed disease characteristics, systemic treatment, and survival in patients with metastatic colorectal cancer (mCRC) in Spain. In total, 2002 patients were enrolled (mean age 65.3 years; 62.7% male). Overall median overall survival (OS) was 26.72 months, and was longer in patients with left-sided tumors (28.85 vs. 21.04 months (right-sided tumors);

Indexed as

colon cancercolonic neoplasmscontinuum of careprognostic factorsreal-world dataSpain

Identifiers

PMID37760572
PMCPMC10526223
OpenAlexW4386837837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.